N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide | 499152-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide
• 英文别名: 3-(4-((3-cyanophenoxy)methyl)-2-(2-(naphthalen-2-yl)ethoxy)phenyl)-N-(3,4-difluorophenylsulfonyl)propanamide；3-[4-[(3-cyanophenoxy)methyl]-2-(2-naphthalen-2-ylethoxy)phenyl]-N-(3,4-difluorophenyl)sulfonylpropanamide
• CAS: 499152-67-9
• 化学式: C₃₅H₂₈F₂N₂O₅S
• 分子量: 626.681
• InChiKey: WLWLJPIELFZZBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  45
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanoic acid 、 3,4-二氟苯磺酰胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(naphthalen-2-yl)ethoxy)-4-(3-cyanophenoxymethyl)phenyl)propanamide
  参考文献：
  名称：

  Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists

  摘要：

  A series of novel N-acylsulfonamide analogs were synthesized and evaluated for their binding affinity and antagonist activity for the EP3 receptor subtype. Representative compounds were also evaluated for their inhibitory effect on PGE(2)-induced uterine contraction in pregnant rats. Among those tested, a series of N-acylbenzenesulfonamide analogs were found to be more potent than the corresponding carboxylic acid analogs in both the in vitro and in vivo evaluations. The structure activity relationships (SAR) are also discussed. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.02.034

文献信息

• CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Tani Kousuke

  公开号：US20090318703A1

  公开（公告）日：2009-12-24

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，对于预防和/或治疗由疼痛、瘙痒、荨麻疹、过敏、尿频、尿液障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病有用。
• Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
  申请人：Tani Kousuke

  公开号：US20060258728A1

  公开（公告）日：2006-11-16

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，可用于预防和/或治疗因疼痛、瘙痒、荨麻疹、过敏、尿频、尿障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病。
• CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1431267A1

  公开（公告）日：2004-06-23

  A carboxylic acid derivative of formula (I): wherein R1 is -COOH, -COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  式(I)的羧酸衍生物： 其中 R1 为-COOH、-COOR6 等；A 为单键、亚烷基等；R2 为烷基、烷氧基等；B 为碳环或杂环；Q 为烷基烯-Cyc2 等；D 为连接链；R3 为烷基、碳环或杂环，或其无毒盐。式（I）化合物能与 PGE2 受体，特别是 EP3 和/或 EP4 亚型结合并显示出拮抗活性，可用于预防和/或治疗诱发疼痛、瘙痒、荨麻疹、过敏、尿频、排尿障碍、老年痴呆症、癌症、痛经、子宫内膜异位症等疾病。
• REMEDY FOR URINARY TRACT DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1642594A1

  公开（公告）日：2006-04-05

  A preventive and/or a remedy for urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence which comprises a combination of compound having antagonism to EP1 with another compound having antagonism to EP3 each selected from among prostaglandin E2 receptors. The combination of an EP1 antagonist with an EP3 antagonist is useful in preventing and/or treating urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence, because of showing effect of improving urine retaining ability, improving bladder compliance, relieving hypertonic detrusor muscle and normalizing bladder perception.

  一种具有尿急、膀胱痛、尿频或尿失禁等症状的尿路疾病的预防和/或治疗方法，它包括具有EP1拮抗作用的化合物与另一种具有EP3拮抗作用的化合物的组合，每种化合物都选自前列腺素E2受体。EP1拮抗剂与EP3拮抗剂的组合有助于预防和/或治疗伴有尿急、膀胱痛、尿频或尿失禁等症状的尿路疾病，因为其显示出改善尿液保留能力、改善膀胱顺应性、缓解高张力的逼尿肌和使膀胱感知正常化的效果。
• Remedy for urinary tract diseases
  申请人：Maruyama Takayuki

  公开号：US20070167500A1

  公开（公告）日：2007-07-19

  A preventive and/or a remedy for urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence which comprises a combination of compound having antagonism to EP 1 with another compound having antagonism to EP 3 each selected from among prostaglandin E 2 receptors. The combination of an EP 1 antagonist with an EP 3 antagonist is useful in preventing and/or treating urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence, because of showing effect of improving urine retaining ability, improving bladder compliance, relieving hypertonic detrusor muscle and normalizing bladder perception.